Dangerous Drug: Fondaparinux(fon dah pear’ ah nucks)
Arixtra
PREGNANCY CATEGORY B
Drug Classes
Antithrombotic
Factor Xa inhibitor
Therapeutic Actions
Blocks naturally occurring factor Xa, leading to an alteration in the clot formation process; decreasing the risk of clot and thrombus formation.
Indications
Prevention of venous thromboembolic events (including DVT and pulmonary emboli) in patient undergoing surgery for hip fracture, hip replacement, knee replacement or undergoing abdominal surgery
Extended prophylaxis of DVT, which may lead to pulmonary embolism in patients undergoing hip fracture surgery
Treatment of acute DVT in conjunction with warfarin
Treatment of acute pulmonary embolism when administered in conjunction with warfarin when initial therapy is administered in the hospital
Contraindications and Cautions
Contraindicated with hypersensitivity to fondaparinux, severe renal impairment, adults weighing less than 50 kg, active major bleeding, bacterial endocarditis, thrombocytopenia.
Use cautiously with pregnancy or lactation, mild to moderate renal impairment, adults older than 65 yr, bleeding disorders, history of heparin-induced thrombocytopenia, uncontrolled arterial hypertension, GI ulcers, diabetic retinopathy, spinal puncture, neuroaxial anesthesia.
Available Forms
Prefilled syringes—2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, 10 mg/0.8 mL
Dosages
Adults
Prevention of DVT: 2.5 mg/day subcutaneously starting 6–8 hr following surgical closure and continuing for 5–9 days. An additional 24 days may be added after the initial course for patients undergoing hip fracture surgery.
Treatment of DVT, acute pulmonary embolism in conjunction with warfarin: Weight less than 50 kg: 5 mg/day subcutaneously for 5–9 days.
Weight 50–100 kg: 7.5 mg/day subcutaneously for 5–9 days.
Weight more than 100 kg: 10 mg/day subcutaneously for 5–9 days.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
